BiotechTube

Empagliflozin + Empagliflozin + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 1

Conditions

Diabetes Mellitus, Type 1

Trial Timeline

Jun 30, 2015 → Oct 23, 2017

NCT ID
NCT02414958

About Empagliflozin + Empagliflozin + Placebo

Empagliflozin + Empagliflozin + Placebo is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT02414958. Target conditions include Diabetes Mellitus, Type 1.

What happened to similar drugs?

20 of 20 similar drugs in Diabetes Mellitus, Type 1 were approved

Approved (20) Terminated (0) Active (0)
✅add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
✅Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
✅Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
✅exenatide and sitagliptin + exenatide and placeboEli LillyApproved
✅Tirzepatide + PlaceboEli LillyApproved
✅LisproEli LillyApproved
✅ToujeoMIRA PharmaceuticalsApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02414958Phase 3Completed

Competing Products

20 competing products in Diabetes Mellitus, Type 1

See all competitors
ProductCompanyStageHype Score
NEX-22A, a prolonged release formulation of liraglutideNanexa ABPhase 1
23
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
29
MKP10241 + PlaceboMankind PharmaPhase 2
42
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
21
LY3209590 + Insulin DegludecEli LillyPhase 1
29
AC2993Eli LillyPhase 3
40
LY3209590 + PlaceboEli LillyPhase 1
29
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
40
LY2963016 + LantusEli LillyPhase 1
29
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
26
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
43
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
40
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
26
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
36
Placebo + LinagliptinEli LillyPhase 3
40
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
43
teplizumab or placeboEli LillyPhase 1
21
LY2428757 + PlaceboEli LillyPhase 2
35
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
40